On September 28, the COVID-19 inactivated vaccine (Vero cell) independently developed by BioKangtai has been approved by the National Medical Products Administration for clinical trial. It has become the first novel coronavirus vaccine to enter clinical trial in Guangdong Province.
The first phase of the COVID-19 inactivated vaccine production workshop has been completed. It is expected to have an annual production capacity of 100 million doses/year by the end of this year.
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
COVID-19: A Basic Guide to Different Vaccine Types and How They Work
With global push for COVID-19 vaccines, China aims to win friends and cut deals